Skip to main content
. 2019 Jun 19;52(3):45–58. doi: 10.1267/ahc.19006

Fig. 11.

Fig. 11.

Specificity of antibodies confirmed by immunoblotting and immunofluorescence. The position of Novex sharp pre-stained protein standards (kDa) is marked on the right of each blot (A, F, K, and L). Bands near the expected size of each target protein are indicated by arrows in each blot (A, F, K, and L). A. Immunoblotting of control HeLa and cisplatin-treated HeLa cell homogenates with cleaved caspase-3 antibody. Positive bands are only seen in cisplatin-treated HeLa cell homogenates. B–E. Immunofluorescence images of control and cisplatin-treated HeLa cells incubated with cleaved caspase-3 antibody (B and D) and the corresponding Nomarski differential interference-contrast images (C and E). Specific labeling is only seen in cisplatin-treated, apoptosis-induced, HeLa cells. F. Immunoblotting of HeLa cell homogenates with Ki67 antibody. G–J. Immunofluorescence images of HeLa cells incubated with (G) or without (I) Ki67 antibody and the corresponding Nomarski differential interference-contrast images (H and J). K, L. Immunoblotting of mouse parotid gland homogenates with TMEM16A (K) or NKCC1 (L) antibodies.